ALMR
Alamar Biosciences, Inc.
$20.16
-1.71%
$1.4B
No data for this timeframe.
Vol
Market Cap$1.4B
Cap SizeSmall Cap
Insider Activity2B / 0S
Insider Net $$8.0M
Reddit Sentiment67° Warm
SEC Reports15
Recent Activity
May 8, 2026
SEC
Alamar Biosciences reported Q1 2026 revenue of $26.0M, a 99% YoY increase, driven by 178% consumable revenue growth. Net
8-K — Impact 8/10
May 8, 2026
SEC
Alamar Biosciences reported Q1 2026 revenue of $26.0M, up 99% YoY from $13.1M, driven by 178% consumable growth and 78%
PRESS-RELEASE — Impact 7/10
May 8, 2026
earnings
Alamar Biosciences Reports First Quarter 2026 Financial Results
<p>FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a le
Apr 22, 2026
SEC
Alamar Biosciences insiders and a major shareholder jointly purchased $8 million in stock, with Director Naclerio and 10
CLUSTER — Impact 7/10
Apr 20, 2026
Insider
Naclerio Nicholas sold 4,588,364 shares
Director @ $0.00 ($0.00)
Apr 20, 2026
Insider
Naclerio Nicholas sold 5,510,516 shares
Director @ $0.00 ($0.00)
Apr 20, 2026
Insider
Naclerio Nicholas sold 5,510,516 shares
Director @ $0.00 ($0.00)
Price Targets
$30.00
+48.8% upside
Strong Buy
Current $20.16
Low $27.00
Median $30.00
High $35.00
5 analysts
$27.00
$35.00
Analyst Ratings
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 12, 2026 | Leerink Partners | INITIATE | Outperform |
| May 12, 2026 | TD Cowen | INITIATE | Buy |
| May 12, 2026 | JP Morgan | INITIATE | Overweight |
| May 12, 2026 | Stifel | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.32 | $-0.40 — $-0.21 | 4 | |
| Next Q | $-0.21 | $-0.26 — $-0.12 | 4 | |
| Current FY | $-1.46 | $-1.65 — $-1.24 | 4 | |
| Next FY | $-0.70 | $-0.90 — $-0.48 | 52% YoY | 4 |
Latest Reports
BULLISH
8-K
8/10
Alamar Biosciences reported Q1 2026 revenue of $26.0M, a 99% YoY increase, driven by 178% consumable revenue growth. Net
May 8, 2026
BULLISH
PRESS-RELEASE
7/10
Alamar Biosciences reported Q1 2026 revenue of $26.0M, up 99% YoY from $13.1M, driven by 178% consumable growth and 78%
May 8, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 20, 2026 | Naclerio Nicholas | C | $0.00 |
| Apr 20, 2026 | Naclerio Nicholas | J | $0.00 |
| Apr 20, 2026 | Naclerio Nicholas | J | $0.00 |
| Apr 20, 2026 | Naclerio Nicholas | C | $0.00 |
| Apr 20, 2026 | Naclerio Nicholas | BUY | $4.0M |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
9 unique insiders with 2 transactions. Net insider value: $8.0M ($8.0M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 20, 2026 | Naclerio Nicholas | Director | C | 4,588,364 | $0.00 | $0.00 |
| Apr 20, 2026 | Naclerio Nicholas | Director | J | 5,510,516 | $0.00 | $0.00 |
| Apr 20, 2026 | Naclerio Nicholas | Director | J | 5,510,516 | $0.00 | $0.00 |
| Apr 20, 2026 | Naclerio Nicholas | Director | C | 346,020 | $0.00 | $0.00 |
| Apr 20, 2026 | Naclerio Nicholas | Director | BUY | 235,294 | $17.00 | $4.0M |
| Apr 20, 2026 | Naclerio Nicholas | Director | A | 5,686 | $0.00 | $0.00 |
| Apr 20, 2026 | McAnear Justin J. | Chief Financial Officer | A | 37,220 | $0.00 | $0.00 |
| Apr 20, 2026 | Luo Yuling | Chief Executive Officer | C | 1,386,746 | $0.00 | $0.00 |
| Apr 20, 2026 | Luo Yuling | Chief Executive Officer | J | 1,864,065 | $0.00 | $0.00 |
| Apr 20, 2026 | Naclerio Nicholas | Director | C | 3,194,377 | $0.00 | $0.00 |
| Apr 20, 2026 | Naclerio Nicholas | Director | C | 2,862,507 | $0.00 | $0.00 |
| Apr 20, 2026 | Naclerio Nicholas | Director | C | 2,094,266 | $0.00 | $0.00 |
| Apr 20, 2026 | Naclerio Nicholas | Director | C | 5,037,783 | $0.00 | $0.00 |
| Apr 20, 2026 | Naclerio Nicholas | Director | C | 5,000,000 | $0.00 | $0.00 |
| Apr 20, 2026 | McAnear Justin J. | Chief Financial Officer | J | 570,719 | $0.00 | $0.00 |
| Apr 20, 2026 | Luo Yuling | Chief Executive Officer | J | 1,864,065 | $0.00 | $0.00 |
| Apr 20, 2026 | Luo Yuling | Chief Executive Officer | A | 76,509 | $0.00 | $0.00 |
| Apr 20, 2026 | Luo Yuling | Chief Executive Officer | C | 1,020,742 | $0.00 | $0.00 |
| Apr 20, 2026 | Luo Yuling | Chief Executive Officer | C | 880,802 | $0.00 | $0.00 |
| Apr 20, 2026 | Luo Yuling | Chief Executive Officer | C | 366,004 | $0.00 | $0.00 |
| Apr 20, 2026 | Luo Yuling | Chief Executive Officer | J | 266,311 | $0.00 | $0.00 |
| Apr 20, 2026 | Luo Yuling | Chief Executive Officer | J | 42,334 | $0.00 | $0.00 |
| Apr 20, 2026 | Chen Shiping | Chief Operating Officer | C | 320,511 | $0.00 | $0.00 |
| Apr 20, 2026 | Chen Shiping | Chief Operating Officer | J | 722,885 | $0.00 | $0.00 |
| Apr 20, 2026 | Chen Shiping | Chief Operating Officer | J | 722,885 | $0.00 | $0.00 |
| Apr 20, 2026 | Chen Shiping | Chief Operating Officer | A | 37,220 | $0.00 | $0.00 |
| Apr 20, 2026 | Chen Shiping | Chief Operating Officer | C | 247,311 | $0.00 | $0.00 |
| Apr 20, 2026 | Chen Shiping | Chief Operating Officer | C | 73,200 | $0.00 | $0.00 |
| Apr 20, 2026 | Chen Shiping | Chief Operating Officer | C | 176,160 | $0.00 | $0.00 |
| Apr 20, 2026 | Chen Shiping | Chief Operating Officer | J | 300,883 | $0.00 | $0.00 |
| Apr 20, 2026 | Chen Shiping | Chief Operating Officer | J | 12,190 | $0.00 | $0.00 |
| Apr 20, 2026 | White Timothy Ogden | President | J | 454,583 | $0.00 | $0.00 |
| Apr 20, 2026 | White Timothy Ogden | President | A | 37,220 | $0.00 | $0.00 |
| Apr 20, 2026 | White Timothy Ogden | President | J | 454,583 | $0.00 | $0.00 |
| Apr 20, 2026 | White Timothy Ogden | President | J | 29,357 | $0.00 | $0.00 |
| Apr 20, 2026 | Witney Frank | Director | J | 49,627 | $0.00 | $0.00 |
| Apr 20, 2026 | Chambers Rebecca | Director | J | 140,612 | $0.00 | $0.00 |
| Apr 20, 2026 | Illumina Innovation Fund II GP, L.L.C. | 10%+ Owner | C | 4,588,364 | $0.00 | $0.00 |
| Apr 20, 2026 | Illumina Innovation Fund II GP, L.L.C. | 10%+ Owner | J | 5,510,516 | $0.00 | $0.00 |
| Apr 20, 2026 | Illumina Innovation Fund II GP, L.L.C. | 10%+ Owner | J | 5,510,516 | $0.00 | $0.00 |
| Apr 20, 2026 | Illumina Innovation Fund II GP, L.L.C. | 10%+ Owner | C | 346,020 | $0.00 | $0.00 |
| Apr 20, 2026 | Illumina Innovation Fund II GP, L.L.C. | 10%+ Owner | C | 5,000,000 | $0.00 | $0.00 |
| Apr 20, 2026 | Illumina Innovation Fund II GP, L.L.C. | 10%+ Owner | BUY | 235,294 | $17.00 | $4.0M |
| Apr 20, 2026 | Illumina Innovation Fund II GP, L.L.C. | 10%+ Owner | C | 3,194,377 | $0.00 | $0.00 |
| Apr 20, 2026 | Illumina Innovation Fund II GP, L.L.C. | 10%+ Owner | C | 2,862,507 | $0.00 | $0.00 |
| Apr 20, 2026 | Illumina Innovation Fund II GP, L.L.C. | 10%+ Owner | C | 2,094,266 | $0.00 | $0.00 |
| Apr 20, 2026 | Illumina Innovation Fund II GP, L.L.C. | 10%+ Owner | C | 5,037,783 | $0.00 | $0.00 |
| Apr 20, 2026 | Qiming Corporate GP VI, Ltd. | 10%+ Owner | C | 113,625 | $0.00 | $0.00 |
| Apr 20, 2026 | Qiming Corporate GP VI, Ltd. | 10%+ Owner | C | 154,425 | $0.00 | $0.00 |
| Apr 20, 2026 | Qiming Corporate GP VI, Ltd. | 10%+ Owner | J | 185,163 | $0.00 | $0.00 |
15 SEC filing reports analyzed. Sentiment: 10 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 5.6/10.
BULLISH
8-K
8/10
Alamar Biosciences reported Q1 2026 revenue of $26.0M, a 99% YoY increase, driven by 178% consumable
May 8, 2026
BULLISH
PRESS-RELEASE
7/10
Alamar Biosciences reported Q1 2026 revenue of $26.0M, up 99% YoY from $13.1M, driven by 178% consum
May 8, 2026
BULLISH
CLUSTER
7/10
Alamar Biosciences insiders and a major shareholder jointly purchased $8 million in stock, with Dire
Apr 22, 2026
BULLISH
EFFECT
7/10
Alamar Biosciences' IPO registration has become effective, allowing the company to begin selling sha
Apr 21, 2026
BULLISH
CLUSTER
7/10
Two insiders at Alamar Biosciences, Inc. (ALMR) — Director Nicholas Naclerio and 10% owner Illumina
Apr 21, 2026
BULLISH
8-K
8/10
Alamar Biosciences completed its IPO, raising approximately $219.9 million by selling 12,937,500 sha
Apr 20, 2026
BULLISH
424B4
7/10
Alamar Biosciences has priced its IPO of 11.25 million shares at $17.00 per share, raising $177.9 mi
Apr 17, 2026
BULLISH
EFFECT
7/10
Alamar Biosciences' IPO registration has become effective, allowing the company to begin selling sha
Apr 17, 2026
NEUTRAL
3
2/10
Frank Witney, a reporting person at Alamar Biosciences, filed a Form 3 to report initial beneficial
Apr 17, 2026
NEUTRAL
3
2/10
Ian W. Ratcliffe, a reporting owner at Alamar Biosciences, Inc., filed a Form 3 to report his initia
Apr 17, 2026
NEUTRAL
3
2/10
Rebecca Chambers, a director or officer of Alamar Biosciences, filed a Form 3 to report initial bene
Apr 17, 2026
NEUTRAL
3
3/10
Nicholas Naclerio, a director of Alamar Biosciences (ALMR), filed a Form 3 to report beneficial owne
Apr 17, 2026
NEUTRAL
3
3/10
Justin J. McAnear, CFO of Alamar Biosciences, filed a Form 3 disclosing an initial grant of stock op
Apr 17, 2026
BULLISH
S-1/A
7/10
Alamar Biosciences is conducting an IPO to raise capital, leveraging strong revenue growth (196% YoY
Apr 16, 2026
BULLISH
S-1/A
7/10
Alamar Biosciences is conducting an IPO to raise capital, leveraging strong revenue growth (195% YoY
Apr 13, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Analyst Price Targets
$30.00 mean target
+48.8% upside
Strong Buy (1.60)
$27.00 Low
$35.00 High
| Metric | Value |
|---|---|
| Current Price | $20.16 |
| Target Low | $27.00 |
| Target Mean | $30.00 |
| Target Median | $30.00 |
| Target High | $35.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.60) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.32 | $-0.40 | $-0.21 | — | — | — | $0.0B | — | 4 |
| Next Q 2026-09-30 |
$-0.21 | $-0.26 | $-0.12 | — | — | — | $0.0B | — | 4 |
| Current FY 2026-12-31 |
$-1.46 | $-1.65 | $-1.24 | — | — | — | $0.1B | — | 4 |
| Next FY 2027-12-31 |
$-0.70 | $-0.90 | $-0.48 | 51.7% | — | — | $0.2B | 43.1% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.322 | |
| 7d ago | $0.000 | -0.322 |
| 30d ago | $0.000 | -0.322 |
| 60d ago | $0.000 | -0.322 |
| 90d ago | $0.000 | -0.322 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 4 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 12, 2026 | Leerink Partners | INITIATE | — | Outperform |
| May 12, 2026 | TD Cowen | INITIATE | — | Buy |
| May 12, 2026 | JP Morgan | INITIATE | — | Overweight |
| May 12, 2026 | Stifel | INITIATE | — | Buy |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 25, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 25, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Biggest insider buys this week
▲ 1
💬 0
⚡ 0.5
May 8, 2026
earnings
Alamar Biosciences Reports First Quarter 2026 Financial Results
<p>FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling